- AstraZeneca (AZN +0.5%) may be a step behind Roche (RHHBY.OB +0.9%), Bristol-Myers (BMY +0.3%), and Merck (MRK -1.3%) when it comes to developing immunotherapies to treat cancer, but "the field is still very open for combinations and [AZN is] very much in the race," the company's head of biologics Bahija Jallal says.
- The "breadth" of AZN's pipeline and the "pace of cancer drug development" may help AZN catch up to industry leaders quickly, Reuters notes.
- One promising candidate is the PD-L1 blocker MEDI4376 which may prove most effective when paired with other drugs such as tremelimumab which "works in a similar way to BMY's Yervoy."
- Late last month, Roche reported positive results for its PD-LI drug MPDL3280A in NSCLC.
AstraZeneca well positioned to join cancer immunotherapy race: Reuters
Oct 14 2013, 14:14 ET